L

Lineage Cell Therapeutics Inc
TASE:LCTX

Watchlist Manager
Lineage Cell Therapeutics Inc
TASE:LCTX
Watchlist
Price: 216.7 ILS 10.67% Market Closed
Market Cap: 109m ILS
Have any thoughts about
Lineage Cell Therapeutics Inc?
Write Note

Lineage Cell Therapeutics Inc
Minority Interest

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Lineage Cell Therapeutics Inc
Minority Interest Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Minority Interest CAGR 3Y CAGR 5Y CAGR 10Y
L
Lineage Cell Therapeutics Inc
TASE:LCTX
Minority Interest
-$1.4m
CAGR 3-Years
-8%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Minority Interest
$39m
CAGR 3-Years
13%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amgen Inc
NASDAQ:AMGN
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Minority Interest
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Lineage Cell Therapeutics Inc
Glance View

Market Cap
109m ILS
Industry
Biotechnology

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company is headquartered in Carlsbad, California and currently employs 57 full-time employees. The firm is engaged in developing cell therapies for unmet medical needs. The company is focused on developing therapies for degenerative retinal diseases, neurological conditions associated with demyelination and aiding the body in detecting and combating cancer. Specifically, it is testing therapies to treat dry age-related macular degeneration, spinal cord injuries and non-small cell lung cancer. The firm has three allogeneic cell therapy programs: OpRegen, OPC1 and VAC2. OpRegen is a retinal pigment epithelium cell replacement therapy being developed for the treatment of advanced dry age-related macular degeneration (AMD) with geographic atrophy. OPC1 is an oligodendrocyte progenitor cell therapy that is being developed for acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy of antigen-presenting dendritic cells that is being developed for non-small cell lung cancer.

LCTX Intrinsic Value
156.5 ILS
Overvaluation 28%
Intrinsic Value
Price
L

See Also

What is Lineage Cell Therapeutics Inc's Minority Interest?
Minority Interest
-1.4m USD

Based on the financial report for Sep 30, 2024, Lineage Cell Therapeutics Inc's Minority Interest amounts to -1.4m USD.

What is Lineage Cell Therapeutics Inc's Minority Interest growth rate?
Minority Interest CAGR 5Y
3%

Over the last year, the Minority Interest growth was 7%. The average annual Minority Interest growth rates for Lineage Cell Therapeutics Inc have been -8% over the past three years , 3% over the past five years .

Back to Top